Chengdu Olymvax Biopharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Chengdu Olymvax Biopharmaceuticals's earnings have been declining at an average annual rate of -9.2%, while the Biotechs industry saw earnings growing at 8.9% annually. Revenues have been growing at an average rate of 11.1% per year.
Key information
-9.2%
Earnings growth rate
-10.5%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 11.1% |
| Return on equity | -2.0% |
| Net Margin | -2.5% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Chengdu Olymvax Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 500 | -12 | 353 | 144 |
| 31 Dec 23 | 496 | 18 | 336 | 115 |
| 30 Sep 23 | 529 | 17 | 365 | 132 |
| 30 Jun 23 | 548 | 24 | 367 | 132 |
| 31 Mar 23 | 561 | 37 | 357 | 124 |
| 31 Dec 22 | 547 | 27 | 364 | 122 |
| 30 Sep 22 | 573 | 70 | 368 | 93 |
| 30 Jun 22 | 551 | 97 | 358 | 65 |
| 31 Mar 22 | 477 | 81 | 315 | 62 |
| 31 Dec 21 | 487 | 108 | 305 | 56 |
| 30 Sep 21 | 405 | 78 | 268 | 46 |
| 30 Jun 21 | 378 | 65 | 256 | 49 |
| 31 Mar 21 | 328 | 50 | 225 | 45 |
| 31 Dec 20 | 320 | 36 | 229 | 43 |
| 31 Dec 19 | 179 | -31 | 153 | 44 |
| 31 Dec 18 | 76 | -19 | 55 | 31 |
| 30 Jun 18 | 63 | 14 | 47 | 0 |
| 31 Mar 18 | 54 | 7 | 46 | 0 |
| 31 Dec 17 | 45 | 1 | 45 | 0 |
| 30 Sep 17 | 26 | -23 | 50 | 0 |
| 30 Jun 17 | 7 | -48 | 54 | 0 |
| 31 Mar 17 | 4 | -52 | 55 | 0 |
| 31 Dec 16 | 0 | -56 | 55 | 0 |
| 30 Sep 16 | 0 | -51 | 52 | 0 |
| 30 Jun 16 | 0 | -47 | 49 | 0 |
| 31 Mar 16 | 0 | -50 | 51 | 0 |
| 31 Dec 15 | 0 | -52 | 52 | 0 |
| 31 Dec 14 | 0 | -30 | 26 | 0 |
Quality Earnings: 688319 is currently unprofitable.
Growing Profit Margin: 688319 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688319 is unprofitable, and losses have increased over the past 5 years at a rate of 9.2% per year.
Accelerating Growth: Unable to compare 688319's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688319 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: 688319 has a negative Return on Equity (-2.01%), as it is currently unprofitable.